Illumina, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Illumina develops and sells genetic analysis systems, instruments, consumables, and related services for sequencing, genotyping, gene expression, and molecular diagnostics. The filing covers the 13-week quarter and 39-week year-to-date period ended October 2, 2011, compared with October 3, 2010.
Financial Performance and Position
| Metric | Q3 2011 | Q3 2010 | YTD 2011 | YTD 2010 |
|---|---|---|---|---|
| Total revenue | $235.5 million | $237.3 million | $805.5 million | $641.4 million |
| Gross profit | $157.1 million | $157.1 million | $538.5 million | $435.4 million |
| Gross margin | 66.7% | 66.2% | 66.9% | 67.9% |
| Income from operations | $36.8 million | $57.3 million | $172.2 million | $143.0 million |
| Net income | $20.2 million | $35.4 million | $74.9 million | $86.5 million |
| Diluted EPS | $0.15 | $0.24 | $0.52 | $0.61 |
- Q3 revenue was essentially flat year over year, while year-to-date revenue increased 26%, driven by HiSeq 2000 shipments and consumables growth.
- Q3 consumables revenue increased 9% to $144.9 million, but instrument revenue declined 18% to $71.8 million. Service and other revenue increased 20% to $15.2 million.
- Q3 operating margin was approximately 15.6%, versus 24.2% in the prior-year quarter. Year-to-date operating margin was approximately 21.4%, versus 22.3%.
- Operating expenses increased 21% in Q3 and 25% year to date, primarily due to higher personnel costs, headcount growth, headquarters relocation costs, and other operating expenses.
- Interest expense increased to $25.6 million year to date, and other expense included a $37.6 million loss on extinguishment of convertible debt.
- Effective tax rates were 27.5% for Q3 and 33.6% year to date. Management expected the full-year rate to approximate the 35% U.S. federal statutory rate.
- Cash and cash equivalents were $229.8 million at October 2, 2011. Short-term investments were $902.3 million, providing total cash and short-term investments of approximately $1.1 billion.
- Year-to-date operating cash flow was $249.8 million, compared with $191.1 million in the prior-year period. Capital expenditures were $50.7 million, and investing cash outflow was $358.0 million.
- Convertible debt principal outstanding consisted of $920.0 million of 0.25% notes due 2016 and $40.1 million of 0.625% notes due 2014. Net carrying value of long-term debt was $765.1 million at October 2, 2011.
Material Changes Versus the Prior Comparable Period
- Year-to-date revenue rose 26%, but net income declined 13% because of higher operating expenses, increased interest expense, and the debt extinguishment loss.
- Q3 instrument demand weakened because of academic funding uncertainty, purchasing delays, excess sequencing capacity, and lower-than-expected Genome Analyzer upgrades to HiSeq 2000 systems.
- Higher-throughput sequencing kits increased capacity but temporarily reduced sequencing runs and consumable revenue per instrument as customers adjusted workflows and awaited additional samples.
- Year-to-date gross margin declined to 66.9% from 67.9%, primarily because of a sales mix shift toward lower-margin instruments and HiSeq 2000 promotional discounts. Q3 gross margin improved because of a shift toward consumables and reduced promotional impact.
- Illumina issued $920.0 million of convertible senior notes due 2016, used $349.9 million to repay 2014 notes upon conversion, and repurchased $570.4 million of common stock year to date, including $314.3 million concurrent with the 2016 notes issuance.
- Headquarters relocation expense was $6.5 million in Q3 and $11.6 million year to date; additional relocation costs were expected after the reporting date.
- Illumina acquired Epicentre in January 2011 for total consideration of approximately $71.4 million, adding sample-preparation reagents and specialty enzymes.
Guidance, Outlook, Risks, and Unusual Items
- Management expected Q4 2011 revenue to exceed Q3 revenue, but anticipated continued pressure from uncertainty in global research funding.
- Management expected MiSeq volume shipments to begin in Q4 2011 after initial commercial shipments began late in Q3.
- On October 25, 2011, Illumina announced a workforce reduction of approximately 200 employees, or 8%, and expected a restructuring charge of approximately $15 million to $17 million, with most of the charge in Q4 2011.
- Management expected additional headquarters relocation expense, including a cease-use loss, accelerated depreciation, and overlapping rent during the transition.
- Approximately one-third of revenue was estimated to be derived directly or indirectly from U.S. NIH funding. The filing cited potential reductions or stagnation in U.S. and international government and academic research funding as a principal risk.
- Other risks include technology and product commercialization, manufacturing execution, competitive developments, customer purchasing delays, economic conditions, tax changes, foreign exchange exposure, and the ability to maintain consumables utilization.
- Pending litigation was described as arising in the ordinary course of business; management could not estimate potential losses but did not expect an aggregate material adverse effect.
- Management stated that existing cash, investments, and operating cash flow were expected to fund operating needs for at least the next 12 months, absent unforeseen circumstances.
Investor Verification Checklist
- Verify whether sequencing instrument demand and consumable revenue per instrument recovered as customers utilized excess capacity and funding conditions evolved.
- Assess the effect of the Q4 2011 restructuring charge and remaining headquarters relocation costs on operating margins and cash flow.
- Review the maturity, conversion conditions, dilution potential, and cash-settlement exposure of the 2014 and 2016 convertible notes.
- Confirm the sustainability of the approximately $1.1 billion liquidity balance after debt repayments, share repurchases, acquisitions, and capital expenditures.
- Monitor NIH and other government research funding trends and their effect on customer purchasing decisions.
- Evaluate whether year-to-date revenue growth can continue without further margin pressure from instrument mix, pricing, and elevated operating expenses.